- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02031614
The Immunomodulatory Effects of Phlebotomy
Study Overview
Detailed Description
The loss of blood by haemorrhage or routine phlebotomy as performed during blood donation by healthy volunteers, has large effects on systemic iron homeostasis. The relative shortage of erythrocytes after blood loss is compensated for by increasing the production of new red cells by the bone marrow. As iron is needed for effective haemoglobin synthesis, the transport of iron to the bone marrow needs to be increased. This is accomplished by the suppression of hepcidin production in the liver. Hepcidin is the central regulator of iron homeostasis. It can regulate serum iron levels effectively by downregulating iron channel ferroportin on iron exporting cells. Hepcidin production is increased in response to inflammation en high systemic iron content, and is suppressed by increased erythrocyte production, hypoxia, anemia, and low systemic iron content. Therefore, blood loss leads to hepcidin suppression, increased release of iron into the circulation and decrease of iron stores.
Alterations in iron metabolism can have immunomodulatory effects. The intra cellular iron content in macropahges and monocytes, has shown pro-inflammatory effects in several investigations. Hepcidin is reported to have pro-inflammatory effects in some reports, and anti-inflammatory effects in others.
Although phlebotomy is routinely performed in blood donors, and seemingly does not have significant health risks, it is highly relevant to know what the effect of phlebotomy is on immunity. Alterations in immunity due to phlebotomy could have beneficial effects, like the suppression of the low grade inflammatory process that contributes to atherosclerosis, but in theory could also contribute to a suppressed innate immune response that could increase the risk of infection. This is not only relevant for blood donors, but also for patients suffering from blood loss and for daily clinical practice in which blood is routinely drawn of patients for laboratory determinations.
Objective: To assess the ex vivo cytokine production of whole blood during 28 days after phlebotomy (routine withdrawal of 500 ml of blood).
Study design: Intervention study in 10 healthy male volunteers.
Study population: 10 healthy male volunteers in the age of 18-35 years.
Intervention (if applicable): Withdrawal of 500 mL of blood at the blood bank (Sanquin, Nijmegen, The Netherlands).
Main study parameters/endpoints:
- Ex vivo cytokine production of whole blood, drawn on day -1, 0, 1, 3, 5, 7, 14, 21, 28.
- Hemoglobin, hematocrit, white blood cell count and differential
- Hepcidin
- Iron parameters (serum iron, transferrin saturation, ferritin)
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
10 healthy young male volunteers will be included in this study. The study consists of 10 visits: 1 screening visit and 9 follow-up visits. The screening visit consists of a medical history questionnaire. On day 0, Phlebotomy of 500 ml of blood will be performed at the Sanquin blood bank, Nijmegen according to normal procedures. Risks associated with phlebotomy are, discomfort during puncture, light-headedness, orthostatic hypotension, vasovagale response, and hematoma at the puncture site.
On day -1, 0, 1, 3, 5, 7, 14, 21 and 28, a volume of 7 mL of blood will be drawn by venapuncture. Associated risks are discomfort during puncture , vasovagale response, and hematoma at the puncture site.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: L T van Eijk, MD, MSc
- Phone Number: +31 24 3653879
- Email: L.vanEijk@Radboudumc.nl
Study Locations
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands, 6500 HB
- Radboudumc
-
Contact:
- L T van Eijk, MD, MSc
- Phone Number: +31 24 3617273
-
Principal Investigator:
- P Pickkers, MD, PhD
-
Sub-Investigator:
- L T van Eijk, MD, MSc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male
- Age >18 and <36 years
- Healthy as concluded from medical history
Exclusion Criteria:
- Having donated blood to the blood bank within one year preceding phlebotomy
- Significant blood loss from trauma within one year preceding phlebotomy
- Having lost > 100 ml of blood due to any cause, within 3 months preceding phlebotomy (not counting blood withdrawn during screening visit)
- Having lost > 50 ml of blood due to any cause, within 1 month preceding phlebotomy (not counting blood withdrawn during screening visit)
- Having lost >20 ml blood due to any cause, within 1 week preceding phlebotomy (not counting blood withdrawn during screening visit)
- Family history of thallasemia, sickle cell disease, hereditary hemochromatosis, or iron refractory iron deficiency anemia
- Signs of history of infection within 2 weeks preceding phlebotomy
- History of frequent vasovagal response
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phlebotomy
Subjects in this arm will undergo phlebotomy of 500 mL of blood.
|
Withdrawal of 500 mL of whole blood.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ex vivo TNF-afpha production of whole blood in reponse to incubation with E. Coli LPS
Time Frame: 1 day before till 28 days after phlebotomy
|
Blood will be drawn on day -1, 0, 1, 3, 5, 7, 14, 21 and 28 after phlebotomy, to assess ex vivo cytokine production.
|
1 day before till 28 days after phlebotomy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ex vivo IL6 and IL-10 production of whole blood in response to incubation with E.Coli LPS
Time Frame: 1 day before till 28 days after phlebotomy
|
Blood will be drawn on day -1, 0, 1, 3, 5, 7, 14, 21 and 28 after phlebotomy, to assess ex vivo cytokine production.
|
1 day before till 28 days after phlebotomy
|
Changes in hemoglobin, hematocrit, white blood cell count and differential
Time Frame: 1 day before till 28 after phlebotomy
|
Hemoglobin, hematocrit, white blood cell count and differential will be determined on day -1, 0, 1, 3, 5, 7, 14, 21 and 28 following the withdrawal of 500 ml of blood at the blood bank
|
1 day before till 28 after phlebotomy
|
Changes in hemoglobin, hematocrit, white blood cell count and differential
Time Frame: 1 day before till 28 after phlebotomy
|
Hemoglobin, hematocrit, white blood cell count and differential will be determined on day -1, 0, 1, 3, 5, 7, 14, 21 and 28 following phlebotomy
|
1 day before till 28 after phlebotomy
|
Changes in plasma hepcidin
Time Frame: 1 day before till 28 after phlebotomy
|
Plasma hepcidin concentration will be determined at various time points during the 28 days of follow-up, following phlebotomy
|
1 day before till 28 after phlebotomy
|
Changes in other markers of iron homeostasis (serum iron, transferrin saturation, ferritin)
Time Frame: 1 day before till 28 after phlebotomy
|
Changes in parameters of iron homeostasis will be determined at various time points during the 28 days of follow-up, following phlebotomy
|
1 day before till 28 after phlebotomy
|
Adverse Events
Time Frame: 1 day before till 28 after phlebotomy
|
Adverse Events will be assessed with every visit
|
1 day before till 28 after phlebotomy
|
Collaborators and Investigators
Investigators
- Principal Investigator: P Pickkers, MD, PhD, Radboud University Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Phlebotomy-2014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Abdelwahed, Mai Mahmoud Mohamed, M.D.UnknownAnemia During PregnancyEgypt
-
University of California, DavisInstituto Mexicano del Seguro Social; Thrasher Research Fund; Mexican National... and other collaboratorsCompleted
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Peking Union Medical College HospitalRecruiting
-
Alexion PharmaceuticalsWithdrawnWarm Autoimmune Hemolytic AnemiaUnited States
Clinical Trials on Phlebotomy
-
Georgetown UniversityNova Southeastern UniversityUnknown
-
The University of Texas Health Science Center,...Completed
-
The University of Texas Health Science Center,...Recruiting
-
Leiden University Medical CenterRecruiting
-
ImmuniconUnknownNeoplasm Metastasis | Colorectal CancerUnited States
-
University of Colorado, DenverCompletedRespiratory Tract Infections | Down Syndrome | Polyendocrinopathies, Autoimmune | AutoimmunityUnited States
-
Milton S. Hershey Medical CenterWithdrawnSepsis | Septic Shock | Multiple Organ Dysfunction | Intra-abdominal Sepsis
-
Stanford UniversityEnrolling by invitation
-
Stanford UniversityCompleted
-
Stanford UniversityCompletedLung CancerUnited States